Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

Core Insights - Mesoblast Limited has appointed Teresa Montagut MD, PhD as the Head of Clinical Development and Medical Affairs to enhance its medical affairs organization and clinical collaborations [1][4] - Teresa Montagut brings extensive experience in medical leadership and pharmaceutical development, having previously worked at Regeneron and led cancer immunotherapy programs at major pharmaceutical companies [2][3] Company Overview - Mesoblast is a global leader in developing allogeneic cellular medicines for severe inflammatory diseases, utilizing a proprietary mesenchymal lineage cell therapy technology platform [5] - The company’s FDA-approved product, Ryoncil, is the first mesenchymal stromal cell therapy for treating steroid-refractory acute graft versus host disease in pediatric patients aged 2 months and older [6] - Mesoblast is developing additional therapies for various inflammatory diseases and has established commercial partnerships in Japan, Europe, and China [7] Intellectual Property and Manufacturing - Mesoblast holds a strong global intellectual property portfolio with over 1,000 granted patents or applications, providing commercial protection until at least 2044 in major markets [8] - The company’s proprietary manufacturing processes enable the production of industrial-scale, cryopreserved, off-the-shelf cellular medicines, ensuring availability to patients worldwide [9]